Tango Therapeutics Inc (TNGX)
Tango Therapeutics, Inc. is a biotechnology company focused on precision oncology, with research and development programs aimed at patients with unmet medical needs. The company is working on methylthioadenosine-cooperative PRMT5 inhibitors, including TNG462, which is being evaluated in a Phase 1/2 clinical trial for pancreatic and lung cancer, and TNG456, a brain-penetrant PRMT5 inhibitor being studied for glioblastoma. Tango is also developing TNG260, designed to address immune evasion linked to STK11 loss-of-function mutations in lung cancer. Founded in 2017, the company is headquartered in Boston, Massachusetts, and its common stock is listed on NASDAQ under the ticker TNGX.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-TNGX
|
$19.71
|
-32.1% Downside
|
Overvalued
|
$44.33
|
52.7% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-39.1x
|
10.7x
|
73.6x
|
3.984 B
|
3.845 B
|
0.8%
|
48.1%
|
52.2
|
—
|
132.9%
|
